,71,72 Clinical data from the KRYSTAL-1 trial validate this, showing that baseline SCC signatures correlate with diminished adagrasib efficacy specifically in the STK11-mutant subgroup; moreover, elevated expression of KRT6A, a marker of squamous differentiation, predicts poor prognosis in patients with adagrasib-treated NSCLC, and is significantly associated with co-occurring KEAP1 and STK11 mutations.46 This evidence concerns the gene STK11 and non-small cell lung carcinoma.